Back to Results
First PageMeta Content
Pharmaceuticals policy / Pharmacy / Drug discovery / Health economics / Pharmaceutical Benefits Scheme / Pharmaceutical industry / Orphan drug / Food and Drug Administration / Rare disease / Pharmaceutical sciences / Pharmacology / Health


LIFE SAVING DRUGS PROGRAMME POST MARKET REVIEW ISSUES PAPER APRIL 2015
Add to Reading List

Document Date: 2015-04-10 01:05:20

Open Document

File Size: 1,27 MB

Share Result on Facebook

Company

Post Market Review / Agency for the Evaluation / /

Continent

Australia / /

Country

United States / Netherlands / Australia / /

Currency

USD / /

/

Event

FDA Phase / /

Holiday

Commonwealth Day / Commonwealth Day of Australia / /

IndustryTerm

patient applications / health technology assessment report / reference / /

MedicalCondition

rare diseases / disease / rare/ultra-rare disease / Rare Disease / relevant disease / diseases / another disease / /

Organization

Drugs Department / Medicines Control Agency of the United Kingdom / European Agency for the Evaluation of Medicinal Products / Paroxysmal Nocturnal Haemoglobinuria Disease Advisory Committee / Pharmaceutical Benefits Advisory Committee / Fabry Disease Advisory Committee / Food and Drug Administration / Department of Health Privacy Contact / Department of Industry / National Science Foundation / Bureau of Pharmaceutical Assessment of Canada / DAC / Infantile-onset Pompe Disease Advisory Committee / Disease Advisory Committees / Therapeutic Goods Administration / Medicines Evaluation Board / Gaucher Disease Advisory Committee / Medical Products Agency of Sweden / Department of Health / Mucopolysaccharidosis Disease Advisory Committee / University of Adelaide Health Technology Assessment / LSDP / /

Position

advocate / Chief Medical Officer / Governor / Minister / Evaluator / Pharmacist / supplier Approved pharmacist / delegate / the Secretary / treating physician / Chair / General / Secretary / Officer / /

Product

LSDP / /

Technology

PDF / /

URL

http /

SocialTag